A further possible strategy to inhibit CYP51A1TM indirectly could be represented by the modulation of RNF185 activity, such as via gene therapy, for those cancers where it is underexpressed (i.e., HCC, PTC, prostate carcinoma). This evidence concerns the gene RNF185 and prostate carcinoma.